Basic Information
| LncRNA/CircRNA Name | HIF1A-AS2 |
| Synonyms | HIF1A-AS2, 3'aHIF-1A, aHIF |
| Region | GRCh38_14:61715558-61751097 |
| Ensemble | ENSG00000258667 |
| Refseq | NR_045406 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Western blot, RNAi, other |
| Sample | bladder cancer tissues and cell lines (T24, 5637, and SW780) |
| Expression Pattern | up-regulated |
| Function Description | Mechanically, we found that HIF1A-AS2 suppressed the transcription activity of p53 family proteins by promoting the expression of high-mobility group A1 (HMGA1). The induction of HMGA1 physically interacts with p53, p63, and p73, and therefore constrains their transcriptional activity on Bax. Knockdown of HIF1A-AS2 or HMGA1 rescued the expression of Bax, which therefore enhanced the killing effect of Cis. Furthermore, we also found that the expression of HIF1A-AS2 was higher in the human bladder tumor tissues after Cis treatment, and was positive correlated to the expression of HIF1? and HMGA1. This study suggests that upregulated HIF1A-AS2 hampers the p53 family proteins dependent apoptotic pathway to promote Cis resistance in bladder cancer. |
| Pubmed ID | 30216500 |
| Year | 2019 |
| Title | The Long Noncoding RNA HIF1A-AS2 Facilitates Cisplatin Resistance in Bladder Cancer |
External Links
| Links for HIF1A-AS2 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |